Drug improves speech, memory in Alzheimer's patients
Posted on: Wednesday, 22 March 2006, 20:03 CST
LONDON (Reuters) - A drug used to treat Alzheimer's disease can improve language, memory and understanding in patients with a severe form of dementia, Swedish researchers said on Thursday.
Aricept, which is known generically as donepezil, is marketed by Pfizer and Japan's Eisai Co. Ltd..
When scientists at the Karolinska Institute in Sweden compared the impact of the drug against a placebo in nearly 200 elderly patients they found that people given the drug were able to function better, do daily tasks and were less reliant on nursing care.
Their speech, memory and communication skills also improved.
"We got impressive results," Professor Bengt Winblad, who led the 6-month study, the results of which were published online by The Lancet medical journal.
"We now have a drug that will improve the intellectual capacity of the elderly with severe Alzheimer's disease," he added in an interview.
But in another trial a week ago, Eisai announced that 11 patients with a different form of dementia had died while taking Aricept during a clinical trial.
Patients in that study suffered from vascular dementia, which is caused by a stroke or diseased blood vessels and is the second most common form of dementia after Alzheimer's disease. Nearly 650 patients in the trial were given the drug. There were no deaths among the 326 people who received a placebo.
Winblad emphasized that the drug is not a cure for the illness but it does improve symptoms and enables Alzheimer's patients to function better.
An estimated 12 million people worldwide suffer from Alzheimer's disease. The number is expected to increase as the population ages.
A team of international researchers recently predicted the number of people suffering from dementia worldwide could reach 81 million by 2040.
The progressive illness robs people of their memory and mental ability.
Source: REUTERS
Related Articles
- Avid Initiates First Phase II Alzheimer's Disease Trial
- Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimer's Disease
- Results From Largest Statin Study of Patients With Alzheimer's Disease Show Lipitor(R) Has No Significant Impact on Disease
- PHC Initiates Phase I Alzheimer's Disease Trial
- PHC's Pivotal Research Initiates Largest Phase I Alzheimer's Disease Trial to Date for Major National Sponsor
- EPIX Pharmaceuticals Reports Compelling Clinical Results for PRX-03140 in Alzheimer's Disease; Statistically Significant Improvement in Cognitive Function Achieved Within Two Weeks
- APhA Foundation Announces Recipients of the Incentive Grants Focused on Serving Patients With Alzheimer's Disease and Dementia
- Roche and GE Healthcare to Explore Personalized Medicine in Patients With Alzheimer's Disease
- A Cross-Sectional Study of Neuropsychiatric Symptoms in 435 Patients With Alzheimer's Disease
- Does Donepezil Treatment Slow the Progression of Hippocampal Atrophy in Patients With Alzheimer's Disease?
 |
 |
User Comments (0)
RSS Feeds